Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies

PLoS Neglected Tropical Diseases

Volumn 10, Issue 3, 2016, Pages

  Hotez, Peter J ^a   Pecoul, Bernard ^b   Rijal, Suman ^c   Boehme, Catharina ^d   Aksoy, Serap ^e   Malecela, Mwelecele ^f   Tapia Conyer, Roberto ^g   Reeder, John C ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

^c Drugs for Neglected Diseases Initiative (DNDi)   (India)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^e YALE UNIVERSITY   (United States)

^f NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^g Carlos Slim Health Institute   (Mexico)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTHELMINTHIC VACCINE; ANTIINFECTIVE AGENT; BENZNIDAZOLE; EFLORNITHINE; EMODEPSIDE; FEXINIDAZOLE; FLUBENDAZOLE; INSECTICIDE; LARVICIDAL AGENT; LEISHMANIA VACCINE; MILTEFOSINE; NIFURTIMOX; NITROIMIDAZOLE; OXABOROLE SCYX 7158; PAROMOMYCIN; POSACONAZOLE; RAVUCONAZOLE; RECOMBINANT HUMAN HOOKWORM VACCINE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; BACTERIAL INFECTION; CHAGAS DISEASE; CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DISEASE ELIMINATION; DISEASE TRANSMISSION; HUMAN; LEISHMANIASIS; LYMPHATIC FILARIASIS; NEGLECTED DISEASE; NONHUMAN; ONCHOCERCIASIS; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TRANSLATIONAL RESEARCH; TROPICAL DISEASE; VECTOR CONTROL; VIRUS INFECTION; ANIMAL; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DISEASE ERADICATION; NEGLECTED DISEASES; PROCEDURES; TROPIC CLIMATE;

ANIMALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DISEASE ERADICATION; HUMANS; NEGLECTED DISEASES; TRANSLATIONAL MEDICAL RESEARCH; TROPICAL CLIMATE;

EID: 84962169828     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003895     Document Type: Review

References (91)

1. Hotez P, (2013) Forgotten People, Forgotten Diseases: The Neglected Tropical Diseases and their Impact on Global Health and Development. Washington, D.C.: ASM Press.
2. Molyneux DH, Hotez PJ, Fenwick A, (2005) "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med2: e336. 16212468
3. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, et al. (2006) Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med3: e102. 16435908
4. Lammie PJ, Fenwick A, Utzinger J, (2006) A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol22: 313–321. 16713738
5. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med357: 1018–1027. 17804846
6. Hotez PJ, Fenwick A, Savioli L, Molyneux DH, (2009) Rescuing the bottom billion through control of neglected tropical diseases. Lancet373: 1570–1575. doi: 10.1016/S0140-6736(09)60233-619410718
7. World Health Organization (2010) Working to overcome the global impact of neglected tropical diseases: First WHO report on neglected tropical diseases. Geneva. 172 p.
8. Hotez PJ, Alvarado M, Basanez MG, Bolliger I, Bourne R, et al. (2014) The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis8: e2865. doi: 10.1371/journal.pntd.000286525058013
9. World Health Organization (2015) Investing to overcome the global impact of neglected tropical diseases: Third WHO report on neglected tropical diseases. Geneva. 191 p.
10. Hotez PJ, Velasquez RM, Wolf JE, Jr. (2014) Neglected tropical skin diseases: their global elimination through integrated mass drug administration?JAMA Dermatol150: 481–482. doi: 10.1001/jamadermatol.2013.875924671756
11. World Health Organization (2014) Preventive chemotherapy: planning, requesting medicines, and reporting. Wkly Epidemiol Rec89: 61–71. 24707511
12. Hotez PJ, (2013) NTDs V.2.0: "blue marble health"—neglected tropical disease control and elimination in a shifting health policy landscape. PLoS Negl Trop Dis7: e2570. doi: 10.1371/journal.pntd.000257024278496
13. Hotez P, (2014) Blue Marble Health: A New Presidential Roadmap for Global Poverty-Related Diseases. Baker Institute for Public Policy.
14. Uniting to Combat Neglected Tropical Diseases. The London Declaration. http://unitingtocombatntds.org/resource/london-declaration. Accessed February 22, 2015.
15. Hotez PJ, Pecoul B, (2010) "Manifesto" for advancing the control and elimination of neglected tropical diseases. PLoS Negl Trop Dis4: e718. doi: 10.1371/journal.pntd.000071820520793
16. Keenan JD, Hotez PJ, Amza A, Stoller NE, Gaynor BD, et al. (2013) Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. PLoS Negl Trop Dis7: e2562. doi: 10.1371/journal.pntd.000256224340111
17. Brooker SJ, Nikolay B, Balabanova D, Pullan RL. Global feasibility assessment of interrupting the transmission of soil-transmitted helminths: a statistical modelling study.Lancet Infect Dis. 2015 Apr 14. pii: S1473-3099(15)70042-3. doi: 10.1016/S1473-3099(15)70042-3 [Epub ahead of print] Global feasibility assessment of interrupting the transmission of soil-transmitted helminths: a statistical modelling study.
18. Colley DG, Morbidity control of schistosomiasis by mass drug administration: how can we do it best and what will it take to move on to elimination?Trop Med Health. 2014Jun;42(2 Suppl):25–32. doi: 10.2149/tmh.2014-S0425425948
19. Kim YE, Remme JH, Steinmann P, Stolk WA, Roungou JB, Tediosi F, Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl Trop Dis. 2015Apr10;9(4):e0003664. doi: 10.1371/journal.pntd.0003664.eCollection201525860569
20. Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, et al. (2013) The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment. Lancet Glob Health1: e371–379. doi: 10.1016/S2214-109X(13)70078-025104602
21. Jackson Y, Chatelain E, Mauris A, Holst M, Miao Q, et al. (2013) Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment. BMC Infect Dis13: 85. doi: 10.1186/1471-2334-13-8523406191
22. Schmid C, Kuemmerle A, Blum J, Ghabri S, Kande V, et al. (2012) In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis6: e1920. doi: 10.1371/journal.pntd.000192023209861
23. World Health Organization (2012) Research Priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. Geneva. Technical Report Series Number 975 Technical Report Series Number 975. 100 p.
24. Brun R, Don R, Jacobs RT, Wang MZ, Barrett MP, (2011) Development of novel drugs for human African trypanosomiasis. Future Microbiol6: 677–691. doi: 10.2217/fmb.11.4421707314
25. Ward CP, Wong PE, Burchmore RJ, de Koning HP, Barrett MP, (2011) Trypanocidal furamidine analogues: influence of pyridine nitrogens on trypanocidal activity, transport kinetics, and resistance patterns. Antimicrob Agents Chemother55: 2352–2361. doi: 10.1128/AAC.01551-1021402852
26. Chatelain E, (2015) Chagas disease drug discovery: toward a new era. J Biomol Screen20: 22–35. doi: 10.1177/108705711455058525245987
27. BIO Ventures for Global Health. (2015) Global Health Primer. http://www.bvgh.org/Current-Programs/Neglected-Disease-Product-Pipelines/Global-Health-Primer.aspx. Accessed February 1, 2015.
28. Loiseau PM, Cojean S, Schrevel J, (2011) Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite18: 115–119. 21678786
29. Clinicaltrials.gov Expanded Access WR 279396 Topical Cream Treatment for Uncomplicated Cutaneous Leishmaniasis (WR279396RX).
30. Clinical trials.gov. (2014) Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia). https://clinicaltrials.gov/ct2/show/NCT00606580. Accessed January 23, 2015.
31. World Health Organization, TDR (2012) Research Priorities for Helminth Infections. Geneva.
32. Olliaro P, Seiler J, Kuesel A, Horton J, Clark JN, et al. (2011) Potential drug development candidates for human soil-transmitted helminthiases. PLoS Negl Trop Dis5: e1138. doi: 10.1371/journal.pntd.000113821695247
33. Balasegaram M, Bréchot C, Farrar J, Heymann D, Ganguly N, Khor M, et al. (2015) A Global Biomedical R&D Fund and Mechanism for Innovations of Public Health Importance. PLoS Med12(5): e1001831. doi: 10.1371/journal.pmed.100183125962119
34. HOOKVAC. (2014) HOOKVAC. The Human Hookworm Vaccine http://hookvac.eu/. Accessed May 27, 2015.
35. Hotez PJ, Diemert D, Bacon KM, Beaumier C, Bethony JM, et al. (2013) The Human Hookworm Vaccine. Vaccine31Suppl 2: B227–232. doi: 10.1016/j.vaccine.2012.11.03423598487
36. Zhan B, Beaumier CM, Briggs N, Jones KM, Keegan BP, et al. (2014) Advancing a multivalent 'Pan-anthelmintic' vaccine against soil-transmitted nematode infections. Expert Rev Vaccines13: 321–331. doi: 10.1586/14760584.2014.87203524392641
37. Riveau G, Deplanque D, Remoue F, Schacht AM, Vodougnon H, et al. (2012) Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis6: e1704. doi: 10.1371/journal.pntd.000170422802974
38. Curti E, Kwityn C, Zhan B, Gillespie P, Brelsford J, et al. (2013) Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother9: 2342–2350. 23899507
39. Tendler M, Simpson AJ, (2008) The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop108: 263–266. doi: 10.1016/j.actatropica.2008.09.00218834847
40. Siddiqui AA, Siddiqui BA, Ganley-Leal L, (2011) Schistosomiasis vaccines. Hum Vaccin7: 1192–1197. doi: 10.4161/hv.7.11.1701722048120
41. El Ridi R, Tallima H, Dalton JP, Donnelly S, (2014) Induction of protective immune responses against schistosomiasis using functionally active cysteine peptidases. Front Genet5: 119. doi: 10.3389/fgene.2014.0011924847355
42. Hotez PJ, Bottazzi ME, Zhan B, Makepeace BL, Klei TR, et al. (2015) The Onchocerciasis Vaccine for Africa—TOVA—Initiative. PLoS Negl Trop Dis9: e0003422. doi: 10.1371/journal.pntd.000342225634641
43. Bergquist R, Lustigman S, (2010) Control of important helminthic infections vaccine development as part of the solution. Adv Parasitol73: 297–326. doi: 10.1016/S0065-308X(10)73010-420627146
44. Lightowlers MW, (2013) Control of Taenia solium taeniasis/cysticercosis: past practices and new possibilities. Parasitology140: 1566–1577. doi: 10.1017/S003118201300100523947762
45. You H, McManus DP, (2015) Vaccines and diagnostics for zoonotic schistosomiasis japonica. Parasitology142: 271–289. doi: 10.1017/S003118201400131025359506
46. Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, et al. (2013) Case study for a vaccine against leishmaniasis. Vaccine31Suppl 2: B244–249. doi: 10.1016/j.vaccine.2012.11.08023598489
47. Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG, (2012) Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol3: 144. doi: 10.3389/fimmu.2012.0014422701453
48. Kamhawi S, Aslan H, Valenzuela JG, (2014) Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?Front Public Health2: 99. doi: 10.3389/fpubh.2014.0009925152872
49. Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, et al. (2012) Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis205: 853–863. doi: 10.1093/infdis/jir84222301630
50. Dumonteil E, Bottazzi ME, Zhan B, Heffernan MJ, Jones K, et al. (2012) Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines11: 1043–1055. doi: 10.1586/erv.12.8523151163
51. Gupta S, Wan X, Zago MP, Sellers VC, Silva TS, et al. (2013) Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease. PLoS Negl Trop Dis7: e2018. doi: 10.1371/journal.pntd.000201823350012
52. Pereira IR, Vilar-Pereira G, Marques V, da Silva AA, Caetano B, et al. (2015) A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog11: e1004594. doi: 10.1371/journal.ppat.100459425617628
53. Lee BY, Bacon KM, Bailey R, Wiringa AE, Smith KJ, (2011) The potential economic value of a hookworm vaccine. Vaccine29: 1201–1210. doi: 10.1016/j.vaccine.2010.12.00421167860
54. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, et al. (2012) The economic value of a visceral leishmaniasis vaccine in Bihar state, India. Am J Trop Med Hyg86: 417–425. doi: 10.4269/ajtmh.2012.10-041522403311
55. Bacon KM, Hotez PJ, Kruchten SD, Kamhawi S, Bottazzi ME, et al. (2013) The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine31: 480–486. doi: 10.1016/j.vaccine.2012.11.03223176979
56. Lee BY, Bacon KM, Wateska AR, Bottazzi ME, Dumonteil E, et al. (2012) Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vaccin Immunother8: 1293–1301. doi: 10.4161/hv.2096622894964
57. Policy Cures (2013) G-Finder Factsheet: Diagnostic R&D for Neglected Diseases.
58. Molyneux DH, (2014) Neglected tropical diseases: now more than just 'other diseases'—the post-2015 agenda. Int Health6: 172–180. doi: 10.1093/inthealth/ihu03724969646
59. Murray S, (2014) Diagnostic tools as essential as drugs in the fight to control disease. ftcom: The Financial Times Ltd.
60. Buscher P, Gilleman Q, Lejon V, (2013) Rapid diagnostic test for sleeping sickness. N Engl J Med368: 1069–1070. doi: 10.1056/NEJMc121037323484849
61. Sternberg JM, Gierlinski M, Bieler S, Ferguson MA, Ndung'u JM, (2014) Evaluation of the diagnostic accuracy of prototype rapid tests for human African trypanosomiasis. PLoS Negl Trop Dis8: e3373. doi: 10.1371/journal.pntd.000337325521120
62. Ochodo EA, Gopalakrishna G, Spek B, Reitsma JB, van Lieshout L, Polman K, Lamberton P, Bossuyt PM, Leeflang MM, Circulating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areas. Cochrane Database Syst Rev. 2015Mar11;3:CD009579. doi: 10.1002/14651858.CD009579.pub225758180
63. Ndung'u JM, Bieler S, Roscigno G, (2010) "Piggy-backing" on diagnostic platforms brings hope to neglected diseases: the case of sleeping sickness. PLoS Negl Trop Dis4: e715. doi: 10.1371/journal.pntd.000071520520801
64. Schofield CJ, Dias JC, (1999) The Southern Cone Initiative against Chagas disease. Adv Parasitol42: 1–27. 10050271
65. Mallet J, (1989) The evolution of insecticide resistance: Have the insects won?Trends Ecol Evol4: 336–340. doi: 10.1016/0169-5347(89)90088-821227375
66. Davies JB, (1994) Sixty years of onchocerciasis vector control: a chronological summary with comments on eradication, reinvasion, and insecticide resistance. Annu Rev Entomol39: 23–45. 8135499
67. Marcombe S, Poupardin R, Darriet F, Reynaud S, Bonnet J, et al. (2009) Exploring the molecular basis of insecticide resistance in the dengue vector Aedes aegypti: a case study in Martinique Island (French West Indies). BMC Genomics10: 494. doi: 10.1186/1471-2164-10-49419857255
68. Rowland M, Boko P, Odjo A, Asidi A, Akogbeto M, et al. (2013) A new long-lasting indoor residual formulation of the organophosphate insecticide pirimiphos methyl for prolonged control of pyrethroid-resistant mosquitoes: an experimental hut trial in Benin. PLoS One8: e69516. doi: 10.1371/journal.pone.006951623936033
69. Federici B, Park H- W, Sakano Y, Shively J, (2006) Insecticidal Protein Crystals of Bacillus thuringiensis. In: Inclusions in Prokaryotes: Springer Berlin Heidelberg. pp. 195–236.
70. Thomsen EK, Strode C, Hemmings K, Hughes AJ, Chanda E, et al. (2014) Underpinning sustainable vector control through informed insecticide resistance management. PLoS One9: e99822. doi: 10.1371/journal.pone.009982224932861
71. International Glossina Genome I, (2014) Genome sequence of the tsetse fly (Glossina morsitans): vector of African trypanosomiasis. Science344: 380–386. doi: 10.1126/science.124965624763584
72. Neafsey DE, Waterhouse RM, Abai MR, Aganezov SS, Alekseyev MA, et al. (2015) Mosquito genomics. Highly evolvable malaria vectors: the genomes of 16 Anopheles mosquitoes. Science347: 1258522. doi: 10.1126/science.125852225554792
73. Cirimotich CM, Ramirez JL, Dimopoulos G, (2011) Native microbiota shape insect vector competence for human pathogens. Cell Host Microbe10: 307–310. doi: 10.1016/j.chom.2011.09.00622018231
74. Dennison NJ, Jupatanakul N, Dimopoulos G, (2014) The mosquito microbiota influences vector competence for human pathogens. Curr Opin Insect Sci3: 6–13. 25584199
75. Marinotti O, Jasinskiene N, Fazekas A, Scaife S, Fu G, et al. (2013) Development of a population suppression strain of the human malaria vector mosquito, Anopheles stephensi. Malar J12: 142. doi: 10.1186/1475-2875-12-14223622561
76. Fu G, Lees RS, Nimmo D, Aw D, Jin L, et al. (2010) Female-specific flightless phenotype for mosquito control. Proc Natl Acad Sci U S A107: 4550–4554. doi: 10.1073/pnas.100025110720176967
77. Masiga D, Obiero G, Macharia R, Mireji P, Christoffels A, (2014) Chemosensory receptors in tsetse flies provide link between chemical and behavioural ecology. Trends Parasitol30: 426–428. doi: 10.1016/j.pt.2014.06.00725017128
78. Xu P, Choo YM, De La Rosa A, Leal WS, (2014) Mosquito odorant receptor for DEET and methyl jasmonate. Proc Natl Acad Sci U S A111: 16592–16597. doi: 10.1073/pnas.141724411125349401
79. McBride CS, Baier F, Omondi AB, Spitzer SA, Lutomiah J, et al. (2014) Evolution of mosquito preference for humans linked to an odorant receptor. Nature515: 222–227. doi: 10.1038/nature1396425391959
80. Potter CJ, (2014) Stop the biting: targeting a mosquito's sense of smell. Cell156: 878–881. doi: 10.1016/j.cell.2014.02.00324581489
81. Esterhuizen J, Rayaisse JB, Tirados I, Mpiana S, Solano P, et al. (2011) Improving the cost-effectiveness of visual devices for the control of riverine tsetse flies, the major vectors of human African trypanosomiasis. PLoS Negl Trop Dis5: e1257. doi: 10.1371/journal.pntd.000125721829743
82. Solano P, Torr SJ, Lehane MJ, (2013) Is vector control needed to eliminate gambiense human African trypanosomiasis?Front Cell Infect Microbiol3: 33. doi: 10.3389/fcimb.2013.0003323914350
83. World Health Organization, TDR. (2015) TDR For Research on Diseases of Poverty. Implementation Research Toolkit. http://www.who.int/tdr/publications/topics/ir-toolkit/en/. Accessed February 5, 2015.
84. Peters D, Tran N, Adam T, Research AfHPaS, Organization WH. (2013) Implementation research in health: a practical guide. http://www.who.int/iris/handle/10665/91758#sthash.xU3pWET2.dpuf. Accessed March 2, 2015.
85. World Health Organization (2013) Research for universal health coverage: World health report 2013. 168 p.
86. Terry RF, Salm JF, Jr.Nannei C, Dye C, (2014) Creating a global observatory for health R&D. Science345: 1302–1304. doi: 10.1126/science.125873725214621
87. Reeder JC, Guth JA, (2015) What have we learned from 40 years of supporting research and capacity building?PLoS Negl Trop Dis9: e3355. doi: 10.1371/journal.pntd.000335525569251
88. Certain E, Terry RF, Zicker F, (2015) Shaping the research agenda. PLoS Negl Trop Dis9: e3350. doi: 10.1371/journal.pntd.000335025569230
89. Group CDIS (2010) Community-directed interventions for priority health problems in Africa: results of a multicountry study. Bull World Health Organ88: 509–518. doi: 10.2471/BLT.09.06920320616970
90. World Health Organization. (2015) African Programme for Onchocerciasis Control. Achievements of Community-directed treatment with ivermectin. http://www.who.int/apoc/cdti/achievements/en/. Accessed February 9, 2015.
91. Ogundahunsi OA, Vahedi M, Kamau EM, Aslanyan G, Terry RF, et al. (2015) Strengthening Research Capacity-TDR's Evolving Experience in Low- and Middle-Income Countries. PLoS Negl Trop Dis9: e3380. doi: 10.1371/journal.pntd.000338025569232